Lirimilast

Lirimilast (BAY 19-8004) is a potent, selective and orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of 49 nM. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease (COPD) . Lirimilast has potently anti-inflammatory properties[1][2].

Product Specifications

CAS Number

[329306-27-6]

Product Name Alternative

BAY 19-8004

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lirimilast.html

Concentration

10mM

Purity

98.69

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N)NC1=C(C(C2=CC=C(Cl)C=C2Cl)=O)OC3=CC(OS(=O)(C)=O)=CC=C13

Molecular Formula

C17H12Cl2N2O6S

Molecular Weight

443.26

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Grootendorst DC, et al. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD) . Pulm Pharmacol Ther. 2003;16 (6) :341-7.|[2] Peter Norman. PDE4 inhibitors: sustained patenting activity as leading drugs near the market. Exp. Opin. Ther. Patents (2000) 10 (9) :1415-1427.